Drug Sample Reporting: FDA Doesn’t Want Signatures, But Firms Need Them On File
Executive Summary
Revisions to draft guidance implementing Affordable Care Act streamline some requirements – allowing sponsors, authorized distributors, or even third parties to submit reports to FDA.
You may also be interested in...
Drug Sample Reporting Must Be Streamlined, PhRMA Tells FDA
FDA could be flooded with “millions of duplicative signatures” every time a health care practitioner requests a drug sample, the trade group warns.
Drug Sample Distribution Reporting Deadline Extended By FDA
FDA is giving manufacturers six more months to provide HHS with information on the distribution of drug samples as it plans further guidance; the Affordable Care Act mandated that the data be submitted by April 1.
US FDA’s Science Strategies Program Aims To Proactively Tackle Drug Development Hurdles
The goal of the Office of New Drugs’ initiative is to develop and execute, in a cross-disciplinary manner, strategic plans to address substantive development hurdles in specific therapeutic areas. This approach already has been used for non-healing, chronic wounds and is being expanded to neurodegenerative and rare diseases, OND’s Peter Stein tells the Pink Sheet.